Non-Invasive Prenatal Testing in High-Risk Populations: A Clinical Review

Cell-free foetal DNA (cfDNA) analysis has fundamentally altered the landscape of prenatal screening over the past decade. By detecting foetal chromosomal material in the maternal circulation, non-invasive prenatal testing (NIPT) offers sensitivity and specificity for common aneuploidies that substantially exceed conventional first-trimester combined screening. However, the translation of these performance metrics into clinical practice — particularly in high-risk populations — demands a nuanced understanding of the test’s limitations, the significance of discordant results, and the irreplaceable role of informed counselling.

Performance in High-Risk Populations

The sensitivity of NIPT for trisomy 21 exceeds 99% in prospective validation studies, with a false-positive rate below 0.1%. Similar performance has been demonstrated for trisomy 18 and, to a somewhat lesser degree, trisomy 13. In high-risk populations — those with advanced maternal age, prior aneuploid pregnancy, or an increased nuchal translucency — the positive predictive value rises substantially compared with average-risk screening populations, making NIPT an appropriate first-line investigation rather than an adjunct to combined screening.

Sex chromosome aneuploidies and rare autosomal conditions extend the scope of NIPT but with considerably reduced positive predictive values. Clinicians should be particularly cautious in interpreting results for conditions such as 22q11.2 deletion syndrome, where NIPT sensitivity and specificity remain insufficiently validated for the full breadth of clinical variants.

“A high-risk NIPT result is not a diagnosis. Its role is to identify those pregnancies most likely to benefit from invasive diagnostic testing, not to supersede it.”

Discordant and Failed Results

Confined placental mosaicism remains the most common explanation for a discordant NIPT result, in which a positive screen is not confirmed at invasive testing. Clinicians should counsel patients that this outcome, while reassuring for the fetus, does not entirely eliminate risk — confined placental mosaicism is associated with adverse placental function and may warrant enhanced fetal growth surveillance. In cases of a positive NIPT result with a normal fetal structural survey and a negative invasive test result, close liaison with clinical genetics is appropriate.

Failed NIPT results, often secondary to insufficient foetal fraction, occur in approximately 1–5% of cases and are more common in pregnancies complicated by elevated BMI or gestational diabetes. A failed result should not be dismissed; emerging data suggest an association between low foetal fraction and adverse perinatal outcomes, including placental insufficiency and preterm birth.

Counselling Considerations

Pre-test counselling must encompass the probabilistic nature of the test, the distinction between screening and diagnosis, and the management implications of high-risk and discordant results. Patients should be aware that NIPT does not replace the structural survey and that the scope of conditions screened varies between testing platforms and laboratory providers. In the context of a multiple pregnancy — particularly following IVF — the performance characteristics differ, and counselling should be adapted accordingly.

Conclusion

NIPT occupies a central and expanding role in the prenatal diagnostic pathway, offering substantial clinical value when deployed and interpreted thoughtfully. For the referring clinician, the most important contribution is not the test itself but the quality of the pre- and post-test consultation: ensuring that patients understand what the result does and does not tell them, and that subsequent management is guided by the full clinical picture rather than by a number in isolation.